Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Supriya Lifescience
Mid Cap•448 Employees•IPO 2021
Current Price
₹604.80
23.95 (4.12%)Updated
Today's Range
₹585.80
₹606.95
₹604.80
52 Week Range
52W Low₹573.40
52W High₹842.00
₹604.80
Downside5.48%
Upside39.22%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹5,388.32 Cr
Market Cap
Total market value of companyP/E Ratio
29.21
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.42
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹23.05
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
9.70%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
27.50%
ROCE
Return on Capital Employed. >15% is goodNet Margin
25.19%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
20.69%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
17.45%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-9.69%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-22.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.01
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹123.85
Book Value
Net asset value per shareDividend Yield
0.12%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
68.30%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Robust profitability with 36.70% OPM, 20.80% ROE, and 27.50% ROCE.
- •Very low debt-to-equity ratio (0.01) indicates strong financial health.
Weaknesses
5 points- •Elevated P/E ratio (35.53) compared to sector suggests potential overvaluation.
- •Recent quarterly sales declined 9.69%, net profit fell 22.10%, raising concerns.
Opportunities
3 points- •Pharmaceutical and healthcare sector offers sustained growth from global health awareness.
- •R&D pipeline for novel drugs and expansion into new therapeutic areas.
Threats
4 points- •Intense competition from established players could pressure margins and market share.
- •Evolving regulatory landscape and compliance requirements pose operational and profitability risks.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹654.87 | +₹50.07 | +8.28% |
| R3 | ₹633.72 | +₹28.92 | +4.78% |
| R2 | ₹620.33 | +₹15.53 | +2.57% |
| R1 | ₹612.57 | +₹7.77 | +1.28% |
| PIVOT | ₹599.18 | -5.62 | -0.93% |
| CURRENT | ₹604.80 | - | - |
| S1 | ₹549.12 | -₹55.68 | -9.21% |
| S2 | ₹570.27 | -₹34.53 | -5.71% |
| S3 | ₹578.03 | -₹26.77 | -4.43% |
| S4 | ₹591.42 | -₹13.38 | -2.21% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+195.8% vs avg
4.79L
(09 Mar 2026)Delivery %+4.7% vs avg
57.4%
(09 Mar 2026)Avg Volume (20D)20-day average
1.62L
(09 Feb - 09 Mar)Avg Delivery %Trend ↓
52.7%
(09 Feb - 09 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Aarti Pharmalabs Ltd |
 Blue Jet Healthcare Ltd |
 FDC Ltd |
 Marksans Pharma Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Senores Pharmaceuticals Ltd |
 Sequent Scientific Ltd |
 Shilpa Medicare Ltd |
 SMS Pharmaceuticals Ltd |
 Sun Pharma Advanced Research Company Ltd |
 Strides Pharma Science Ltd |
 Sun Pharmaceutical Industries Ltd |
 Zota Health Care Ltd |
About
Supriya Lifescience Ltd
Supriya Lifescience Limited is a global player in the pharmaceutical industry, specializing in the research, development, manufacturing, and sale of bulk drugs and pharmaceutical chemicals. Their primary focus is on the creation and distribution of Active Pharmaceutical Ingredients (APIs) used in a wide range of therapeutic areas.
The company's API portfolio encompasses various therapeutic segments including anti-histamines, anti-allergics, anti-asthmatics, decongestants, analgesics, antipyretics, anesthetics, anti-hypertensives, anti-malarials, vitamins, and products for treating gout. They also cater to the oncology, veterinary, and general pharmaceutical markets with a diverse range of products.
Beyond their core API business, Supriya Lifescience has expanded into the development and commercialization of specialized healthcare products. This includes GelHeal, a wound care solution, and Quickblue, a kit for the early detection of oral cancer. This diversification demonstrates their commitment to addressing a broader spectrum of healthcare needs.
Looking towards the future, Supriya Lifescience is actively engaged in the research and development of novel drugs across numerous therapeutic areas. Their pipeline includes potential treatments for depression, inflammation, various types of cancers, diabetes, obesity, migraine, and ataxia. They are also exploring opportunities in the development of contrast media, hormones, antibiotics, smoking cessation aids, and veterinary APIs. This aggressive R&D strategy signifies their commitment to innovation and expansion within the pharmaceutical landscape.
Established in 1987 and headquartered in Mumbai, India, Supriya Lifescience has a long history of serving the global pharmaceutical market. Their integrated approach, combining research, manufacturing, and sales, allows them to maintain a strong position in the competitive pharmaceutical industry and continue to explore new avenues for growth and development.
COMPANY FACTS - SUPRIYA
Registered Address
Sonawala Road Goregoan, 207/208, Udyog Bhavan
Mumbai
MAHARASHTRA
IN
Tel: 912240332727
Website:https://supriyalifescience.com/
Investor Relations:http://www.supriyalifescience.com/investor-relation/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 448
IPO Date: 28/12/2021
MANAGEMENT - SUPRIYA
Dr. Satish Wagh
Executive Chairman of the Board
Mr. Krishna Raghunathan
Chief Financial Officer
Ms. Prachi Sathe
Company Secretary and Compliance Officer
Ms. Saloni Wagh
Managing Director, Whole-Time Director
Ms. Shivani Wagh
Joint Managing Director, Whole-Time Director
Mr. Balasaheb Sawant
Whole-Time Director
Ms. Smita Wagh
Whole-Time Director
Mrs. Neelam Arora
Non-Executive Independent Director
Dr. Sunil Bhagwat
Non-Executive Independent Director
Shri. Dileep Jain
Non-Executive Independent Director
Mr. Dinesh Modi
Non-Executive Independent Director
Dr. Ganapati Yadav
Non-Executive Independent Director
Investor Questions Answered
Supriya Lifescience Ltd (SUPRIYA) Stock FAQs
Get answers to the most common questions about Supriya Lifescience Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Supriya Lifescience Ltd (SUPRIYA) is ₹604.8. Today, the stock has gained by ₹23.95 (4.12%), trading in a range of ₹585.8 to ₹606.95. The stock opened at ₹590 with a trading volume of 1,05,837 shares.
Supriya Lifescience Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,388.32 crores, P/E ratio of 29.21, ROE of 9.70%, and ROCE of 27.50%. The dividend yield stands at 0.12%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Supriya Lifescience Ltd (SUPRIYA) is ₹842, while the 52-week low is ₹573.4. Currently trading at ₹604.8, the stock is 11.7% away from its 52-week low and 28.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Supriya Lifescience Ltd stock at ₹604.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 29.21 and P/B ratio of N/A. Today's performance shows a gain of 4.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Supriya Lifescience Ltd offers a dividend yield of 0.12%, which means for every ₹100 invested at the current price of ₹604.8, you can expect to receive approximately ₹0.12 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Supriya Lifescience Ltd's key financial metrics include: P/E Ratio: 29.21, P/B Ratio: N/A, ROE: 9.70%, ROCE: 27.50%, Dividend Yield: 0.12%, EPS: ₹23.05, Book Value: ₹123.85, Debt-to-Equity: 0.01, and Current Ratio: N/A. The company's market cap stands at ₹5,388.32 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Supriya Lifescience Ltd stock opened at ₹590 and is currently trading at ₹604.8, showing a gain of ₹23.95 (4.12%). The intraday high is ₹606.95 and low is ₹585.8. The trading volume stands at 1,05,837 shares, indicating moderate market participation today.
Supriya Lifescience Ltd has a Price-to-Earnings (P/E) ratio of 29.21, which means investors are willing to pay ₹29.21 for every ₹1 of earnings. With an EPS of ₹23.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Supriya Lifescience Ltd has a market capitalization of ₹5,388.32 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹604.8) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Supriya Lifescience Ltd has a book value of ₹123.85 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹604.8, which is 388.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Supriya Lifescience Ltd has a Return on Equity (ROE) of 9.70% and Return on Capital Employed (ROCE) of 27.50%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Supriya Lifescience Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Supriya Lifescience Ltd has a debt-to-equity ratio of 0.01, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Supriya Lifescience Ltd has an Earnings Per Share (EPS) of ₹23.05, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹604.8 and P/E ratio of 29.21, investors are paying 29.21 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Supriya Lifescience Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Supriya Lifescience Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Supriya Lifescience Ltd stock, consider: 1) Fundamental Analysis - Review P/E (29.21), ROE (9.70%), debt-to-equity (0.01), and growth rates. 2) Technical Analysis - Check 52-week range (₹573.40 - ₹842.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹604.80) with book value (₹123.85) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Supriya Lifescience Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹604.8 is 30140x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Supriya Lifescience Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹573.40 - ₹842.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.01 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,05,837 shares. 5) Valuation Risk - P/E of 29.21 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Supriya Lifescience Ltd operates in the industry with key metrics: P/E ratio of 29.21, ROE of 9.70%, market cap of ₹5,388.32 crores, and dividend yield of 0.12%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.01), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Supriya Lifescience Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹604.8, with a 52-week range of ₹573.40 to ₹842.00. Based on fundamentals like P/E (29.21), ROE (9.70%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Supriya Lifescience Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹604.80. 2) Fundamental Deterioration - Declining ROE (currently 9.70%), increasing debt (D/E: 0.01), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Supriya Lifescience Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.12%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu